


Abstract of the Disclosure

A compound of the formula II



5 wherein

one of  $R^1$  and  $R^2$  is halo and the other is H or halo;

$R^3$  is  $C_1$ - $C_4$  straight or branched chain, optionally fluorinated, alkyl;

$R^4$  is H; or

$R^3$  together with  $R^4$  and the adjoining backbone carbon defines:

10 a spiro- $C_5$ - $C_7$  cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_4$  haloalkyl; or optionally bridged with a methylene group; or

a  $C_4$ - $C_6$  saturated heterocycle having a hetero atom selected from

O, NRa, S,  $S(=O)_2$ ; where Ra is H,  $C_1$ - $C_4$  alkyl or  $CH_3C(=O)$ ;

15  $R^5$  is independently selected from H or methyl;

E is  $-C(=O)-$ ,  $-S(=O)_m-$ ,  $-NR^5S(=O)_m-$ ,  $-NR^5C(=O)-$ ,  $-OC(=O)-$ ,

$R^6$  is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle;

m is independently 0, 1 or 2;

are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.